research Results of stage I in a phase II randomized bilateral comparison of bexarotene 1% topical gel in alopecia areata
Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
Search
forResearch
5 / 1000+ resultsresearch 307 Computer-assisted epitope prediction revealed potential autoantigens associated with human alopecia areata
In this study, researchers observed that alopecia areata patients showed higher Th1 and Th2 responses against specific melanogenesis-related protein epitopes, suggesting a role in disease activity and potential targets for diagnostics and therapies.
research Exploring the hair follicle immune privilege state in nonsegmental vitiligo
This study found that immune privilege is preserved in hair follicles of nonsegmental vitiligo patients compared to those with alopecia areata, potentially protecting follicular melanocytes from autoimmune attacks.
research Abuso infantil: aspectos conductuales y otros problemas relacionados
This article reviews treatment options for androgenetic alopecia and suggests minoxidil 5% for early-stage women and either minoxidil or finasteride for men, without new study results.
research Clinical observation of basic fibroblast growth factor (bFGF) combined with minoxidil in the treatment of male androgenetic alopecia
This study found that combining basic fibroblast growth factor with minoxidil improved hair treatment efficiency and patient satisfaction compared to minoxidil alone for early-stage androgenetic alopecia in men.
Community Join
5 / 1000+ resultscommunity Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
community KX-826 1% Phase II Results from China Just Dropped
KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community The Real Cause Of Androgenetic Alopecia
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
community The mechanism of androgenic alopecia
DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.
Learn
3 / 800 resultslearn GT20029
Experimental topical drug designed to break down androgen receptors
learn Pyrilutamide
Experimental topical anti-androgen, also known as KX-826
learn Alopecia Areata
autoimmune disorder causing patchy hair loss
Clinics
4 / 4 results
Experts
— no results